Drug facts
MoleculeLisinopril
Generics already compete: 11 makers on the market. 73 A-rated products from 11 makers substitute at the counter.
Prinivil was first approved by the FDA on 12/29/1987 under NDA 019558; the application holder is Merck Research Laboratories Div Merck Co Inc. The Orange Book lists NDA 019558 as discontinued.
The latest NADAC for LISINOPRIL 10 MG TABLET is $0.02 per unit (as of 10/28/2026).
Holder Merck Research Laboratories Div Merck Co IncApplication NDA 019558Approved 12/29/1987
01Patents and exclusivity
When competition can legally begin. A generic can launch once both exclusivity and the last listed patent expire, unless a court or settlement says otherwise.
- Latest patent
- No Prinivil patent listed in the Orange Book Orange Book
- Later patents, other products
- Qbrelis 11/06/2035 Orange Book
02Competition
- Generics
- 11 generic makers Orange Book
- First generic approved
- 07/01/2002 Orange Book
Every listingEach listing and maker behind the generics count.
Price erosionHow NADAC moves as generics enter.
PrescribersWho prescribes it, from Medicare data.
Available in the full Lisinopril profile.See what is included
03Supply and price
- FDA drug shortage
- ClearNot on the current shortage list FDA shortages
- NADAC
- $0.02 per unitLISINOPRIL 10 MG TABLET, mid-priced of 6 strengths, as of 10/28/2026 CMS NADAC
- Latest recall
- 11/15/2024Class II, Lisinopril, Evaric Pharmaceuticals Inc. FDA enforcement
04Product
- Application holder
- Merck Research Laboratories Div Merck Co Inc Orange Book
- Application
- NDA 019558 Orange Book
- First approved
- 12/29/1987 Orange Book
- Dosage forms
- solution; tablet
- Routes
- oral
- Other brand names
- QbrelisZestril
- Status
- NDA 019558 discontinued Orange Book
Sources: FDA Orange Book, FDA Purple Book, FDA drug shortages, FDA enforcement reports and CMS NADAC, read through QOPE. Not medical or legal advice.